Inflammation Causes Resistance to Anti-CD20–Mediated B Cell Depletion
Open Access
- 6 June 2016
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 16 (11) , 3139-3149
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (K08AI076631, UO1 AI082196, R43 AI079898)
- Oregon National Primate Research Center (RR00163)
- Medical Research Foundation
- American Heart Association (12FTF120070328, 11FTF7310024)
- American Society of Transplantation
This publication has 59 references indexed in Scilit:
- An Acquired Defect in IgG-Dependent Phagocytosis Explains the Impairment in Antibody-Mediated Cellular Depletion in LupusThe Journal of Immunology, 2011
- Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in miceJournal of Clinical Investigation, 2011
- Neonatal Fc receptor and IgG-based therapeuticsmAbs, 2011
- Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletionArthritis & Rheumatism, 2010
- Recipient B Cells Are Not Required for Graft-Versus-Host Disease InductionTransplantation and Cellular Therapy, 2010
- Prolonged effects of short‐term anti‐CD20 B cell depletion therapy in murine systemic lupus erythematosusArthritis & Rheumatism, 2010
- Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeysJournal of Clinical Investigation, 2010
- Rituximab and Intravenous Immune Globulin for Desensitization during Renal TransplantationNew England Journal of Medicine, 2008
- IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Igα/βJournal of Experimental Medicine, 2007
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004